advanced prostate cancer treatment header graphic
Prostate Problem Guide

Taking A Break From Advanced Prostate Cancer Treatment

Once prostate cancer has moved out of the prostate gland and spread into other areas of the body it is said to be advanced prostate cancer and treatment becomes far more difficult than when cancer is confined to the prostate gland.

As long as your cancer has not spread too far and is not too aggressive it is still possible not simply to treat the condition but in fact to cure it. However, in many cases where cancer has spread widely, or is particularly aggressive, treatment becomes a matter of simply slowing the progression of the disease and providing you with the best possible quality of life.

At present one of the main treatments for advanced prostate cancer is intravenous chemotherapy often using a drug known as docetaxal. This is a very effective drug for many patients and does indeed slow the progression of prostate cancer and extend life for many patients. However, it is not without its side effects which include such things as nausea, loss of appetite, hair loss and an increased risk of infection. It is here therefore that we meet one of the biggest problems in advanced cancer treatment.

If you are treating a condition which cannot be cured and which will eventually kill you, then extending your life by holding back the progress of the disease is fine as long as that treatment provides you with an acceptable quality of life and does not end up being worse than the disease itself.

For many prostate cancer sufferers, who are often in their 60s, 70s or even 80s, chemotherapy is not exactly pleasant but is a price worth paying to buy them some time when they first start their treatment. However, as time goes by and the side effects start to build the picture often changes and many patients soon begin to question whether or not it is all worth it. This of course is never an easy question to answer and must be the subject of a very personal discussion between the patient, his family and his physician.

Many of us will be familiar with this scenario either through our own personal experience of illness or from our experience of seeing a family member of close friend in this situation and will know only too well just how difficult a time it can be.

Now, however, there may be a little light at the end of this tunnel as studies involving a sizeable group of patients with metastatic, androgen-independent prostate cancer suggest that many patients may be able to take a 'chemotherapy holiday' without any significant detriment to their treatment. In other words, after several weeks of chemo, and when the side effects are really beginning to get you down, you may be able to simply stop your treatment for a while and give your body a chance to recover a bit before carrying on with your treatment.

Now it is of course early days yet and nobody is quite sure yet just how long your 'chemo holidays' might be or how often you can take them, but for many advanced prostate cancer sufferers this seemingly small advance in treatment may well make all the difference in the world.

An extract from the prostate cancer glossary:

AGE-ADJUSTED: modified to take account of the age of an individual or group of individuals; for example, average normal PSA values can be adjusted according to age groupings of men; these are PSA levels that are considered 'normal' based on the age of the man.

EJACULATION: the release of semen through the penis during orgasm; ejaculation may be termed 'dry' if there is scanty or no fluid component to the ejaculate resulting from RT or surgery.

MCP: modified citrus pectin; a substance that is able to interfere with prostate cancer growth by preventing cell-cell interaction and adhesiveness by binding to a carbohydrate substance called galectin-3 found on the surface of tumor cells.

STENT: a tube used by a surgeon to drain fluids.

Further information on advanced prostate cancer treatment:

Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer - MarketWatch


ChattahBox

Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer
MarketWatch - Aug 27, 2008
today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX ...
Drug trial halted; Cell Genesys shares plummet San Francisco Chronicle
Cell Genesys Stomped Wall Street Journal Blogs
Cell Genesys Halts Prostate Cancer Trial, Shares Drop 78% eFluxMedia
Pharmalot - CNNMoney.com
all 115 news articles

Bostwick Therapeutics Announces Initiation of Novel Phase I/II ... - MarketWatch


Bostwick Therapeutics Announces Initiation of Novel Phase I/II ...
MarketWatch - Sep 5, 2008
The study investigators, Drs. Duke Bahn and Mark Scholz, will introduce the study at the 2008 meeting of the Prostate Cancer Research Institute ( www. ...

EDAP to Present At 19th Annual Wall Street Analyst Forum - MarketWatch


EDAP to Present At 19th Annual Wall Street Analyst Forum
MarketWatch - Sep 5, 2008
Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a ...